肥大细胞白血病中的 II 型肥大细胞:不常见但临床意义重大

EJHaem Pub Date : 2024-04-08 DOI:10.1002/jha2.893
Constance P. Chen, Dong Chen
{"title":"肥大细胞白血病中的 II 型肥大细胞:不常见但临床意义重大","authors":"Constance P. Chen,&nbsp;Dong Chen","doi":"10.1002/jha2.893","DOIUrl":null,"url":null,"abstract":"<p>A 41-year-old female patient with a past medical history of cutaneous mastocytosis presented with musculoskeletal pain. A whole-body positron emission tomography-computed tomography scan showed diffuse bone marrow (BM) fluorodeoxyglucose uptake, most prominent in the humerus and femur. Her complete blood count showed hemoglobin, 7.2 g/dL; white blood cells, 9.8 × 10<sup>9</sup>/L with eosinophilia (2.79 × 10<sup>9</sup>/L); neutrophils, 4.4 × 10<sup>9</sup>/L; lymphocytes, 2.16 × 10<sup>9</sup>/L; monocytes, 0.37 × 10<sup>9</sup>/L; basophils, 0.03 × 10<sup>9</sup>/L and platelets, 179 × 10<sup>9</sup>/L. Her Wright-Giemsa (WG)-stained peripheral blood showed normal-appearing eosinophils without circulating blasts, atypical lymphocytes, or mast cells (MCs). Her WG-stained BM aspirate smears (Figure 1A and 1B) and Hematoxylin-eosin-stained BM biopsy sections (Figure 1C) revealed 80% of cytologically atypical MCs. These MCs exhibited distinct bilobed or multi-lobed nuclei and metachromatic intracytoplasmic granules, morphologically consistent with type II (immature) MCs (denoted with asterisks at 1000X magnification in Panels A–C). They expressed CD25, CD117, and tryptase by immunohistochemical stains and were positive for <i>KIT</i> D816V (variant allele frequency [VAF], 11%) and <i>DNMT3A</i> R899C (VAF, 46%) mutations by a next-generation sequencing study. The cytogenetic study result was normal. The residual trilineage hematopoiesis was markedly decreased with normal morphology. The patient was diagnosed with MC leukemia (MCL) and was refractory to multiple lines of therapy, including Avapritinib.</p><p>As shown in this case, it is essential to recognize the type II MCs for both diagnosis and prognostification of MCL. Although this case fulfilled the diagnostic criteria of MCL by both the International Consensus Classification (ICC) and the 5th World Health Organization Classification, the ICC specifically requires more than 20% type II (immature) MCs on the BM smear or biopsy. MCL patients with increased type II MCs often have much worse clinical outcomes.</p><p>Constance Chen drafted the manuscript and made the figure. Dong Chen drafted the manuscript and provided the pathology images of this case.</p><p>The authors declare no conflict of interest.</p><p>The authors have confirmed ethical approval statement is not needed for this submission.</p><p>The authors have confirmed patient consent statement is not needed for this submission.</p><p>The authors have confirmed clinical trial registration is not needed for this submission.</p>","PeriodicalId":72883,"journal":{"name":"EJHaem","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.893","citationCount":"0","resultStr":"{\"title\":\"Type II mast cells in mast cell leukemia: Uncommon yet clinically significant\",\"authors\":\"Constance P. Chen,&nbsp;Dong Chen\",\"doi\":\"10.1002/jha2.893\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>A 41-year-old female patient with a past medical history of cutaneous mastocytosis presented with musculoskeletal pain. A whole-body positron emission tomography-computed tomography scan showed diffuse bone marrow (BM) fluorodeoxyglucose uptake, most prominent in the humerus and femur. Her complete blood count showed hemoglobin, 7.2 g/dL; white blood cells, 9.8 × 10<sup>9</sup>/L with eosinophilia (2.79 × 10<sup>9</sup>/L); neutrophils, 4.4 × 10<sup>9</sup>/L; lymphocytes, 2.16 × 10<sup>9</sup>/L; monocytes, 0.37 × 10<sup>9</sup>/L; basophils, 0.03 × 10<sup>9</sup>/L and platelets, 179 × 10<sup>9</sup>/L. Her Wright-Giemsa (WG)-stained peripheral blood showed normal-appearing eosinophils without circulating blasts, atypical lymphocytes, or mast cells (MCs). Her WG-stained BM aspirate smears (Figure 1A and 1B) and Hematoxylin-eosin-stained BM biopsy sections (Figure 1C) revealed 80% of cytologically atypical MCs. These MCs exhibited distinct bilobed or multi-lobed nuclei and metachromatic intracytoplasmic granules, morphologically consistent with type II (immature) MCs (denoted with asterisks at 1000X magnification in Panels A–C). They expressed CD25, CD117, and tryptase by immunohistochemical stains and were positive for <i>KIT</i> D816V (variant allele frequency [VAF], 11%) and <i>DNMT3A</i> R899C (VAF, 46%) mutations by a next-generation sequencing study. The cytogenetic study result was normal. The residual trilineage hematopoiesis was markedly decreased with normal morphology. The patient was diagnosed with MC leukemia (MCL) and was refractory to multiple lines of therapy, including Avapritinib.</p><p>As shown in this case, it is essential to recognize the type II MCs for both diagnosis and prognostification of MCL. Although this case fulfilled the diagnostic criteria of MCL by both the International Consensus Classification (ICC) and the 5th World Health Organization Classification, the ICC specifically requires more than 20% type II (immature) MCs on the BM smear or biopsy. MCL patients with increased type II MCs often have much worse clinical outcomes.</p><p>Constance Chen drafted the manuscript and made the figure. Dong Chen drafted the manuscript and provided the pathology images of this case.</p><p>The authors declare no conflict of interest.</p><p>The authors have confirmed ethical approval statement is not needed for this submission.</p><p>The authors have confirmed patient consent statement is not needed for this submission.</p><p>The authors have confirmed clinical trial registration is not needed for this submission.</p>\",\"PeriodicalId\":72883,\"journal\":{\"name\":\"EJHaem\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jha2.893\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EJHaem\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jha2.893\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EJHaem","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jha2.893","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

一名既往有皮肤肥大细胞增多症病史的 41 岁女性患者因肌肉骨骼疼痛就诊。全身正电子发射计算机断层扫描显示骨髓(BM)弥漫性摄取氟脱氧葡萄糖,肱骨和股骨最为突出。她的全血细胞计数显示:血红蛋白 7.2 g/dL;白细胞 9.8 × 109/L,嗜酸性粒细胞增多(2.79 × 109/L);中性粒细胞 4.4 × 109/L;淋巴细胞 2.16 × 109/L;单核细胞 0.37 × 109/L;嗜碱性粒细胞 0.03 × 109/L;血小板 179 × 109/L。她的 Wright-Giemsa (WG)染色外周血显示嗜酸性粒细胞正常,没有循环中的爆炸细胞、非典型淋巴细胞或肥大细胞(MC)。她的WG染色的骨髓穿刺涂片(图1A和1B)和血栓素-伊红染色的骨髓活检切片(图1C)显示80%的细胞学非典型MC。这些 MCs 表现出明显的双叶或多叶核和变色胞质内颗粒,形态上与 II 型(未成熟)MCs 一致(A-C 组中放大 1000 倍的星号表示)。通过免疫组化染色,它们表达 CD25、CD117 和胰蛋白酶;通过新一代测序研究,它们的 KIT D816V(变异等位基因频率 [VAF],11%)和 DNMT3A R899C(VAF,46%)突变均呈阳性。细胞遗传学检查结果正常。残留的三系造血明显减少,但形态正常。该患者被诊断为MC型白血病(MCL),并且对包括阿伐替尼在内的多种疗法均呈难治性。正如本病例所示,识别II型MC对于MCL的诊断和预后都至关重要。虽然本病例符合国际共识分类(ICC)和世界卫生组织第五次分类的 MCL 诊断标准,但 ICC 明确要求在 BM 涂片或活检中发现 20% 以上的 II 型(未成熟)MC。II型MC增多的MCL患者的临床预后往往更差。作者声明不存在利益冲突。作者已确认本论文不需要伦理批准声明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Type II mast cells in mast cell leukemia: Uncommon yet clinically significant

A 41-year-old female patient with a past medical history of cutaneous mastocytosis presented with musculoskeletal pain. A whole-body positron emission tomography-computed tomography scan showed diffuse bone marrow (BM) fluorodeoxyglucose uptake, most prominent in the humerus and femur. Her complete blood count showed hemoglobin, 7.2 g/dL; white blood cells, 9.8 × 109/L with eosinophilia (2.79 × 109/L); neutrophils, 4.4 × 109/L; lymphocytes, 2.16 × 109/L; monocytes, 0.37 × 109/L; basophils, 0.03 × 109/L and platelets, 179 × 109/L. Her Wright-Giemsa (WG)-stained peripheral blood showed normal-appearing eosinophils without circulating blasts, atypical lymphocytes, or mast cells (MCs). Her WG-stained BM aspirate smears (Figure 1A and 1B) and Hematoxylin-eosin-stained BM biopsy sections (Figure 1C) revealed 80% of cytologically atypical MCs. These MCs exhibited distinct bilobed or multi-lobed nuclei and metachromatic intracytoplasmic granules, morphologically consistent with type II (immature) MCs (denoted with asterisks at 1000X magnification in Panels A–C). They expressed CD25, CD117, and tryptase by immunohistochemical stains and were positive for KIT D816V (variant allele frequency [VAF], 11%) and DNMT3A R899C (VAF, 46%) mutations by a next-generation sequencing study. The cytogenetic study result was normal. The residual trilineage hematopoiesis was markedly decreased with normal morphology. The patient was diagnosed with MC leukemia (MCL) and was refractory to multiple lines of therapy, including Avapritinib.

As shown in this case, it is essential to recognize the type II MCs for both diagnosis and prognostification of MCL. Although this case fulfilled the diagnostic criteria of MCL by both the International Consensus Classification (ICC) and the 5th World Health Organization Classification, the ICC specifically requires more than 20% type II (immature) MCs on the BM smear or biopsy. MCL patients with increased type II MCs often have much worse clinical outcomes.

Constance Chen drafted the manuscript and made the figure. Dong Chen drafted the manuscript and provided the pathology images of this case.

The authors declare no conflict of interest.

The authors have confirmed ethical approval statement is not needed for this submission.

The authors have confirmed patient consent statement is not needed for this submission.

The authors have confirmed clinical trial registration is not needed for this submission.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Issue Information Optimisation of the Danish national haemoglobinopathy screening programme – A prospective intervention study A phase 1 trial of venetoclax in combination with liposomal vincristine in patients with relapsed or refractory B‐cell or T‐cell acute lymphoblastic leukemia: Results from the ECOG‐ACRIN EA9152 protocol Unveiling the nephrotoxic profile of BCR-ABL tyrosine kinase inhibitors: A real-world experience in Africa IDH2 mutation accelerates TPO-induced myelofibrosis with enhanced S100a8/a9 and NFκB signaling in vivo
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1